Clinical Trials Browser

Phase 2/3 × pembrolizumab × 30 days × Clear all

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Phase 2/3 Recruiting

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04534205 2026-04-15

AHEAD-MERIT

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06225596 2026-04-15

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Active not recruiting

Urinary Bladder Neoplasms

NCT06712316 2026-04-15

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-04-07

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT06295731 2026-03-31

HexAgon-HN

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06295809 2026-03-27

INTerpath-007

Phase 2/3 Completed

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases